• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Study: Induced pluripotent stem cells could yield accurate models for vascular disease

June 19, 2017 By Sarah Faulkner

HemoShear TherapeuticsSmooth muscle and vascular endothelial cells induced from pluripotent stem cells could help model rare vascular diseases, according to a study published in Stem Cells Translational Medicine. 

Vascular diseases are tricky to study because they are hard to model and human tissue samples are scarce. An appropriate model for real blood vessels could enable researchers to better evaluate the toxicity of new drugs.

Researchers have already found that vascular endothelial cells (iECs) and smooth muscle cells (iSMCs) can be made from human induced pluripotent stem cells, which can differentiate into all different types of adult human cells.

These cells aren’t derived from an intact blood vessel, so they don’t have all the characteristics of “naturally formed” or primary cells.

Researchers from HemoShear Therapeutics and the University of Cambridge designed a study to test if a co-culture of iECs grown on 1 side of a porous membrane and iSMCS on the other side would mimic the function of primary vascular cells when exposed to blood flow.

“While many studies demonstrate the utility of iECs and iSMCs for vascular applications, none to date have provided a direct comparison of primary to iPSC-derived EC and SMCs,” principal investigator and HemoShear co-founder Brian Wamhoff said in prepared remarks. “We did this by simulating normal blood flow through both the co-culture of iPSC-derived cells or primary cells and then again by simulating blood flow through them under advanced inflammatory conditions, such as hardening of the arteries and exposure to drug treatments.”

“While we found that the iPSC-derived cells didn’t perform quite as well as the primary cells under normal blood flow conditions, when it came to advanced inflammatory and drug-related conditions, the iPSCs performed very well,” Wamhoff added. “Thus, we believe this co-culture may have promise for modeling atherosclerosis or other diseases where no primary cells exist or are challenging to procure.”

“Toxicity of drugs to the blood vessels is a major impediment to the development of new therapies,” Dr. Anthony Atala, editor-in-chief of Stem Cells Translational Medicine, said. “This research may result in a viable system for modeling rare vascular diseases and testing new therapeutic approaches.”

Filed Under: Discovery, Featured, Research & Development, Stem Cells, Vascular Tagged With: hemosheartherapeutics

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS